These observations prompted us to analyze the PP2A phosphorylation/inhibition status in breast cancer cells using a “CPscore” in which value 0 was defined by those breast cancer patients without altered p-PP2A and CIP2A, value 1 for those ones with high p-PP2A or CIP2A overexpressed, and value 2 for the subgroup of breast cancer cases with high p-PP2A and CIP2A overexpression. The gene discussed is PTPA; the disease is breast carcinoma.